JP Morgan Chase
ARTL icon

JP Morgan Chase’s Artelo Biosciences ARTL Stock Holding History

JP Morgan Chase’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17
Closed -$611 – 7450
2023
Q2 		$611 Buy
+17
New +$620 ﹤0.01% 6523

Other funds holding ARTL

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase's ARTL Position: Q3 2023 in Review

JP Morgan Chase sold out of Artelo Biosciences (ARTL) in Q3 2023, closing a stake of 17 shares — an estimated $611 sold.

JP Morgan Chase first reported a position in ARTL in Q2 2023 and held it in 1 quarter. The position peaked at $611 in Q2 2023. 8 funds tracked by Wall St. Rank hold ARTL as of Q3 2023.

  • JP Morgan Chase reported no remaining Artelo Biosciences position as of Q3 2023 after selling out during the quarter.
  • JP Morgan Chase sold 17 Artelo Biosciences shares in Q3 2023, an estimated $611.
  • JP Morgan Chase first reported a position in Artelo Biosciences in Q2 2023 and held it in 1 quarter.
  • JP Morgan Chase's Artelo Biosciences position peaked at $611 in Q2 2023.
  • 8 funds tracked by Wall St. Rank held Artelo Biosciences as of Q3 2023.

Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.